This frame suggests that the APB screening may not be sufficient to correctly estimate the incidence of ALT in clinical tumors as well as that more than one ALT mechanism likely exists [11], thus highlighting that a universal consensus on which could be a reliable marker or a combination of markers that better define the ALT status of a tumor is still urgently needed. Here, GPT is linked to neoplasm.